Suppr超能文献

BRIGHT-HD-A巴西公共卫生获益研究:比较血液透析和血液滤过生存率的观察性研究

BRIGHT-HD-A Brazilian Research Investigation on Public Health Gains Comparing Survival Rates Between Hemodialysis and Hemodiafiltration: An Observational Study.

作者信息

Luciano Eduardo P, Chang João, Arantes Elaine C S, Cordeiro Aline, Reis Sandra F S, Andrade Douglas V, Rocha Whelington F, Magalhães Andrea O, Borges Cynthia M, Elias Rosilene M

机构信息

Splendore Kidney Care, Sao Paulo 01438, Brazil.

Fundação Lia Maria Aguiar, Instituto de Responsabilidade Social Sírio Libanês, Campos do Jordão 12460, Brazil.

出版信息

J Clin Med. 2025 Jun 5;14(11):3981. doi: 10.3390/jcm14113981.

Abstract

High-flux online hemodiafiltration (OL-HDF) appears to be associated with better survival than hemodialysis (HD). In Brazil, OL-HDF is only affordable for patients with private health insurance. Although observational studies have shown a survival advantage with OL-HDF, even in Brazil, it is unclear whether this benefit applies to patients without private health insurance. We compared overall and cardiovascular mortality between OL-HDF and HD in patients treated exclusively through the public health care system. We hypothesized that patients on OL-HDF would have a higher survival rate than those on HD. This is an observational cohort study. Adult patients on maintenance hemodialysis or OL-HDF for at least one month during the period between 1 September 2022 and 1 December 2024 were enrolled into the study. The primary outcome was all-cause mortality. The secondary outcome was cardiovascular mortality. Fine-Gray sub-distribution hazard models were used to evaluate survival in the presence of competing events (kidney transplant and recovery of renal function). Patients on HD (N = 321) and OL-HDF (N = 48) were similar in age, race, sex, and vascular access. Patients on HD were more likely to have diabetes (54.0% vs. 29.2%, = 0.001) and spent more hours per week on dialysis (11.2 ± 1.8 vs. 10.5 ± 1.6 h, = 0.006). In an adjusted Fine-Gray model, the hazard of death for patients on OL-HDF was 68% lower than that for patients on HD, and the risk of death for patients with an arteriovenous fistula was 55% lower compared to those with a catheter. Cardiovascular mortality did not differ between the groups. : These findings suggest that OL-HDF is associated with an overall higher survival rate compared to HD, even for patients without private health insurance.

摘要

高通量在线血液透析滤过(OL-HDF)似乎比血液透析(HD)具有更好的生存率。在巴西,只有拥有私人医疗保险的患者才能负担得起OL-HDF。尽管观察性研究表明OL-HDF具有生存优势,但即使在巴西,尚不清楚这种益处是否适用于没有私人医疗保险的患者。我们比较了仅通过公共医疗系统治疗的患者中OL-HDF和HD的全因死亡率和心血管死亡率。我们假设接受OL-HDF治疗的患者生存率高于接受HD治疗的患者。这是一项观察性队列研究。在2022年9月1日至2024年12月1日期间接受维持性血液透析或OL-HDF至少一个月的成年患者被纳入研究。主要结局是全因死亡率。次要结局是心血管死亡率。使用Fine-Gray亚分布风险模型评估存在竞争事件(肾移植和肾功能恢复)时的生存率。接受HD治疗的患者(N = 321)和接受OL-HDF治疗的患者(N = 48)在年龄、种族、性别和血管通路方面相似。接受HD治疗的患者更有可能患有糖尿病(54.0%对29.2%,P = 0.001),并且每周透析时间更长(11.2±1.8对10.5±1.6小时,P = 0.006)。在调整后的Fine-Gray模型中,接受OL-HDF治疗的患者的死亡风险比接受HD治疗的患者低68%,与使用导管的患者相比,动静脉内瘘患者的死亡风险低55%。两组之间的心血管死亡率没有差异。这些发现表明,即使对于没有私人医疗保险的患者,与HD相比,OL-HDF的总体生存率更高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d6/12155737/e829b196fa4e/jcm-14-03981-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验